by Stephen Levin
When Peter Rule, fresh from his success as president of infusion pump-maker MiniMed Inc. , one of the most successful...
PercuSurge: Picking Up The Pieces
Most of the technological developments that have dramatically changed the cardiovascular device market are the result of innovation by small companies that were able to grow along with their products' successes. More recently, however, the device landscape has changed, especially for cardiovascular companies, primarily with large companies dominating distribution channels, making it tougher for small companies to bring products to market. By identifying an unmet clinical need in interventional cardiology and maintaining a competitive head start, PercuSurge is looking to turn the clock back to the days when a small company could carve out its own niche in this huge market.
More from Business Strategy
• By
Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.
• By
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
• By
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
• By
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
More from In Vivo
• By
Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”
• By
While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.
• By
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy